CAD-LT评分有效预测肝移植候选者显著冠状动脉疾病风险
该回顾性研究纳入1771例肝移植前评估患者,构建CAD-LT评分以预测显著冠状动脉疾病(CAD)。评分将风险分为低(≤2%)、中(3%-9%)、高(≥10%),基于风险的检测算法可识别97%的显著CAD并可能避免不必要的检查。
要点
- CAD-LT评分基于年龄、性别、糖尿病、高血压、吸烟、家族史和个人史预测显著CAD。
- 风险分层:低风险≤2%,中风险3%-9%,高风险≥10%。
- 算法可识别97%显著CAD,并可能避免57%的负荷超声和44%的心导管检查。
核心结论
- CAD-LT评分和算法可有效分层肝移植前显著CAD风险,指导更靶向的检测并减少不必要的检查。
研究设计与样本
- 回顾性研究,纳入2010-2019年在印第安纳大学接受肝移植前评估的患者,共1771例,其中1634例负荷超声和1266例心导管检查结果可用。
主要发现
- 显著CAD的多元回归预测因素包括年龄较大(aOR 1.05;95%CI 1.03-1.08)、男性(1.69;1.16-2.50)、糖尿病(1.57;1.12-2.22)、高血压(1.61;1.14-2.28)、吸烟包年(1.01;1.00-1.02)、CAD家族史(1.63;1.16-2.28)和个人CAD史(6.55;4.33-9.90)。
- CAD-LT评分将显著CAD风险分为低(≤2%)、中(3%-9%)、高(≥10%)。
- 在接受心导管检查的患者中,基于风险的检测算法可识别97%的显著CAD,并可能避免669例负荷超声(57%)和561例心导管检查(44%)。
关键数值与推荐
- 显著CAD定义为需要经皮或外科干预的CAD。
- CAD-LT评分风险分层:低风险≤2%,中风险3%-9%,高风险≥10%。
临床怎么用
- CAD-LT评分和算法(www.cad-lt.com)可用于肝移植前显著CAD风险分层,指导更靶向的心脏评估,减少检测数量并缩短等待时间。
局限性
- 回顾性研究,单中心数据,需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with cirrhosis and significant coronary artery disease (CAD) are at risk of peri-liver transplantation (LT) cardiac events. The coronary artery disease in liver transplantation (CAD-LT) score and algorithm aim to predict the risk of significant CAD in LT candidates and guide pre-LT cardiac evaluation. METHODS: Patients who underwent pre-LT evaluation at Indiana University (2010-2019) were studied retrospectively. Stress echocardiography (SE) and cardiac catheterization (CATH) reports were reviewed. CATH was performed for predefined CAD risk factors, irrespective of normal SE. Significant CAD was defined as CAD requiring percutaneous or surgical intervention. A multivariate regression model was constructed to assess risk factors. Receiver-operating curve analysis was used to compute a point-based risk score and a stratified testing algorithm. RESULTS: A total of 1,771 pre-LT patients underwent cardiac evaluation, including results from 1,634 SE and 1,266 CATH assessments. Risk-adjusted predictors of significant CAD at CATH were older age (adjusted odds ratio 1.05; 95% CI 1.03-1.08), male sex (1.69; 1.16-2.50), diabetes (1.57; 1.12-2.22), hypertension (1.61; 1.14-2.28), tobacco use (pack years) (1.01; 1.00-1.02), family history of CAD (1.63; 1.16-2.28), and personal history of CAD (6.55; 4.33-9.90). The CAD-LT score stratified significant CAD risk as low (≤2%), intermediate (3% to 9%), and high (≥10%). Among patients who underwent CATH, a risk-based testing algorithm (low: no testing; intermediate: non-invasive testing vs. CATH; high: CATH) would have identified 97% of all significant CAD and potentially avoided unnecessary testing (669 SE [57%] and 561 CATH [44%]). CONCLUSIONS: The CAD-LT score and algorithm (available at www.cad-lt.com) effectively stratify pre-LT risk for significant CAD. This may guide more targeted testing of candidates with fewer tests and faster time to waitlist. LAY SUMMARY: The coronary artery disease in liver transplantation (CAD-LT) score and algorithm effectively stratify patients based on their risk of significant coronary artery disease. The CAD-LT algorithm can be used to guide a more targeted cardiac evaluation prior to liver transplantation.
引用
- Rachwan RJ, Kutkut I, Timsina LR, et al. CAD-LT score effectively predicts risk of significant coronary artery disease in liver transplant candidates. J Hepatol. 2021. PMID: 33476745. doi:10.1016/j.jhep.2021.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。